This has been coming since the TGA consultation paper in late 2025. The Australian Medical Association lobbied hard for this — they argued that compounded semaglutide was "undermining the PBS listing" of Ozempic and Wegovy.
Current PBS situation for anyone not across it:
Ozempic: PBS-listed for T2D only (not obesity). Cost with PBS: $42.50 per script (general) or $7.70 (concession).
Wegovy: TGA-approved but NOT PBS-listed. Private script cost: ~$400-450/month.
So if you're using semaglutide for weight loss (not diabetes), you're currently looking at $400/month brand-name or ~$120/month compounded. After July, that $120 option disappears.